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Capsule 
The SCREENIVF is an objective instrument to talk about emotional maladjustment but should 
not be used as a predictive tool until more research is done to improve the predictive value. 
Abstract 
Objective: To examine construct and criterion validity of the Dutch SCREENIVF among 
women and men undergoing a fertility treatment. 
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Design: A prospective longitudinal study nested in a Randomized Controlled Trial. 
Setting: University hospital in the Netherlands.  
Patients: Couples, 468 women and 383 men, undergoing an IVF/ICSI treatment in a fertility 
clinic completed the SCREENIVF.  
Main Outcome Measure(s): Construct and criteria validity of the SCREENIVF. 
Results: The comparative fit index and root mean square error of approximation for women and 
men show a good fit of the factor model. Across time, the sensitivity for Hospital Anxiety and 
Depression Scale subscale in women ranged from 61%-98%, specificity 53%-65%, positive 
predictive value 13%-56%, negative predictive value 70%-99%. The sensitivity scores for men 
ranged from 38%-100%, specificity 71%-75%, positive predictive value 9%-27%, negative 
predictive value 92%-100%. A prediction model revealed that for women 68.7 % of the variance 
in the Hospital Anxiety and Depression Scale on time 1 and 42.5% at time 2 and 38.9% was 
explained by the predictors, the sum score scales of the SCREENIVF. For men, 58.1% of the 
variance in the Hospital Anxiety and Depression Scale on time 1 and 46.5% at time 2 and 37.3% 
at time 3 was explained by the predictors, sum score scales of the SCREENIVF. 
Conclusion: The SCREENIVF has good construct validity but the concurrent validity is better 
than the predictive validity. SCREENIVF will be most effectively used in fertility clinics at the 
start of treatment and should not be used as a predictive tool.  
Key words: screening, validation studies, infertility, psychology, assisted reproductive 
techniques 
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Introduction 
Women and men experience distress and lower quality of life during fertility treatments (1-3). 
There is premature discontinuation in fertility treatments like an In Vitro Fertilization (IVF) and 
IntraCytoplasmic Sperm Injection (ICSI) (4-9). Reasons for discontinuation are multifactorial 
but can be distinguished in being financial, hospital/clinic related, medical, physical and/or 
psychological reasons (4, 8, 10, 11).   
Psychological burden for discontinuation represent 14%, physical burden 6% and relational and 
personal problems almost 17% of cases of treatment discontinuation (7). Early detection of 
psychological vulnerability can be achieved by screening (12). A screening test is not intended to 
be diagnostic but to sort patients who possibly have psychological vulnerabilities during a 
fertility treatment from those who possibly do not. Early detection (case-finding) of 
psychological vulnerability aims at discovering conditions which already produced pathological 
change but which have not so far reached a stage at which psychological aid is sought 
spontaneously (12). The SCREENIVF was designed for use at the start of a fertility treatment to 
identify women or men at risk for emotional maladjustment after treatment. Additionally patients 
who are identified as at risk could be provided with additional psychosocial support, to prevent 
them from discontinuation of treatment. The advantages of the SCREENIVF, in relation to other 
already existing screening instruments, is that it identifies five risk areas in the field of emotional 
maladjustment (13, 14). 
The development of the SCREENIVF is based on two studies which revealed the following risk 
factors for increased emotional problems: pre-treatment anxiety, depression, helplessness, less 
acceptance regarding fertility problems, and lack of social support. Based on these studies, the 
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SCREENIVF was developed in a 34 item questionnaire with five risk factors (13, 14). Two 
additional studies investigated the methodological quality of SCREENIVF (15, 16) and one 
study focused on the feasibility of the instrument (17).  
Several checklists exist to investigate the methodological quality of instruments for example the 
COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) 
(18-21). The COSMIN is a checklist to assess the methodological quality of studies evaluating 
health measurement tools (18). Although COSMIN was developed for health-related patient 
reported outcomes it can also be used to evaluate studies about the reliability and validity of the 
SCREENIVF. According to COSMIN checklist an instrument can be based on a reflective or 
formative model of health measurement. The models lead to different specifications for model 
testing (22). In a reflective model all items are a manifestation of the same underlying construct 
and the items are expected to be highly correlated and interchangeable. In a formative model the 
items together form the construct and these items do not need to be correlated. The subscales of 
the SCREENIVF are based on reflective models (i.e., anxiety subscale has 5 anxiety items) but 
each of the SCREENIVF subscales (i.e., anxiety, depression, helplessness, acceptance, social 
support) contributes to risk of psychological vulnerability, and this aspect of the tool makes it a 
formative model. As stated by the COSMIN checklist, studies about the methodological quality 
of an instrument should investigate the following: measurement properties (internal consistency, 
reliability, measurement error), content validity (including face validity), construct validity 
(including structural validity, hypotheses testing, and cross-cultural validity), criterion validity, 
responsiveness, and interpretability (18).  
A Dutch study investigated sensitivity, specificity and negative and positive predictive value of 
the SCREENIVF among 279 women in their first IVF treatment cycle (16). Sensitivity was 69% 
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showing that 46 out of 67 women who were classified as being at risk by the SCREENIVF at T1 
had emotionally maladjusted at time 2. Specificity was 77% showing that 163 out of 212 that 
were correctly classified as not being at risk at T1 had no emotional maladjustment at time 2. 
The negative predictive value was 89% and the positive predictive value was 48% meaning that 
SCREENIVF is better in identifying patients without emotional maladjustment than with 
emotional maladjustment. The Portuguese study focused on reliability and construct validity 
among 291 women and 92 men undergoing an Intra-Uterine Insemination (IUI) or IVF/ICSI 
treatment (15). The set of analyses provided reasonable evidence for the reliability and construct 
validity of SCREENIVF in a different cultural setting.  
Both studies concluded that the SCREENIVF was a reliable and valid instrument to identify 
people at risk for emotional maladjustment. However, reliability and validity analyses to date do 
not fully conform to COSMIN requirements for making this conclusion. Not all areas of validity 
and reliability of the SCREENIVF have been investigated and there is a need especially for 
further testing of construct and criterion validity (18). Construct validity refers to the scores of an 
instrument being consistent with the hypothesised structure of the instrument (23). Although 
shown in a Portuguese population of women and men, this has not yet been evaluated in a 
population of Dutch women and men. Criterion validity can be subdivided in concurrent and 
predictive validity (23). Concurrent validity refers to the degree to which the scores of an 
instrument are an adequate reflection of the scores on a criterion measure assessed at the same 
time. Predictive validity refers to the extent to which scores on one instrument can be used to 
predict future scores on a criterion measure. A criterion measure is an instrument that is reliable 
and valid that can be compared with the new instrument (23).  
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The aim of the present prospective study was to test the construct and criterion validity of the 
Dutch SCREENIVF among women and men about to undergo a fertility treatment. The criterion 
measure of emotional maladjustment was the Hospital Anxiety and Depression Scale (HADS) 
(24). Participants (men and women) completed SCREENIVF and the HADS at the start of an 
IVF/ICSI treatment (to assess concurrent validity), and again during the waiting period after 
embryo transfer and six weeks after embryo transfer (to assess predictive validity) because the 
latter two time points are risk periods for emotional maladjustment (25, 26)  
 
METHOD 
Procedure 
The present prospective longitudinal study was nested in a three-armed Randomized Controlled 
Trial (RCT) and an additional fourth group added after the RCT (Clinical Tials.gov: 
NCT01701011). The ethical committee of the University of Utrecht provided ethical review and 
approval for this study (protocol number 10-174/K). The RCT investigated the effects of the 
Positive Reappraisal Coping Intervention (PRCI) on psychological well-being of women waiting 
for the outcome of their fertility treatment cycle compared to daily emotional monitoring or 
routine care (27-29). The present study used the baseline data from all the participating women 
but used only the data from subsequent measurements (during and after treatment) of women in 
the control group who did not receive the intervention or did not daily monitor emotions. The 
PRCI intervention was aimed at women and not at their partners. Partners of the women 
participating in the RCT were invited to take part in the study of the SCREENIVF. All data of 
the men could be used because they did not receive the intervention.  
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Recruitment for the overall study took place by sending an information letter regarding this study 
to all couples on the waiting list to start an IVF treatment. All couples undergoing a stimulated or 
cryopreserved IVF/ICSI treatment cycle were included. Excluded were women not speaking the 
Dutch language. Couples had to send a reply form or email if they were interested in the study. A 
researcher contacted the interested couples to inform them about the study and to answer any 
questions. Those who decided to participate were sent a written information sheet and an 
informed consent to return in a pre-addressed stamped envelope.   
Couples completed questionnaires at three time points. The first time point was at the start of an 
IVF/ICSI treatment before the first ultrasound, the second time point was on day ten after the 
embryo transfer during the waiting period for the pregnancy test and the last time point was 6 
weeks after the embryo transfer.  
 
Materials 
The Background Information Form (BIF) was only completed by women and contains 16 items 
about demographic (e.g. age, educational status), medical (e.g. previous illness) and 
gynaecological (e.g. infertility diagnosis, previous infertility treatment) characteristics.   
The SCREENIVF contains 34 items on a 4-point Likert scale divided into five domains: state 
anxiety and trait anxiety derived from a short version of Spielberger State and Trait Anxiety 
Inventory (5 items each) (30), depression derived from the short Beck depression Inventory (7 
items) (31), social support derived from the Inventory of Social Involvement (5 items) (32)  and 
helplessness (6 items) and acceptance (6 items) derived from the Illness Cognition Questionnaire 
for IVF patients (13, 33). Use of SCREENIVF results in an at risk score when the score on one 
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of the five risk factors shows clinically relevant problems. In the Dutch population the cut-off 
scores for risk on anxiety are 24 and above, for depression four or higher, social support 15 and 
less, helplessness 14 and above and acceptance 11 and less. The cut-off scores were one standard 
deviation above or below the mean scores of IVF-patients. The SCREENIVF thresholds can 
differ according to population (15). 
The HADS measures general anxiety and depression and contains 14 items (7 items for each 
subscale) that are rated on a 4-point Likert scale (24). Scores on each subscale can be interpreted 
in ranges: normal (0–7), mild (8–10), moderate (11–14) and severe (15–21) anxiety and 
depression (24). Psychometric properties in the Dutch population show a reliable and valid 
instrument (34). 
 
DATA ANALYSES  
IBM SPSS Statistics 20 and R with the lavaan package were used to perform the statistical 
analysis (35). Descriptive statistics were used to describe baseline variables of the BIF. The 
difference between women and men in age at baseline was compared using a paired t-test. 
McNemar’s Chi-square test for categorical, nominal outcomes in related samples (i.e., two 
spouses of same couple) was used for all other baseline variables.   
To investigate the construct validity of the SCREENIVF a confirmatory factor analysis (CFA) 
was conducted. CFA is special case of a structural equation model that estimates the relationship 
between the observed (manifest) variables or indicators and the (unobserved) latent variables or 
factors (36). The CFA was used to test the hypothesised reflective measurement model 
underlying the SCREENIVF against the data obtained to evaluate the hypothesised structural 
9 
 
relations. In accordance with the theoretical model of the SCREENIVF, a CFA was conducted 
with 5 factors representing: anxiety, depression, social support, helplessness and acceptance. The 
CFA was estimated by full-information maximum likelihood (37). The root mean square error of 
approximation (RMSEA) and the comparative fit index (CFI) were used, to test whether the 
model fits the manifest data. When RMSEA < 0.05 and CFI > 0.95 the model is said to have a 
good fit to the data (38). One of the assumptions in CFA is (multivariate) normally distributed 
item distributions, which can be difficult to achieve using single items as indicators (39). In such 
cases the same latent construct can be estimated from multi-item parcels that are the mean of 
several items. The selection of items can be done at random, splitting all odd and even items into 
two parcels or theory based (39-41). The most effective way to create parcels is theory based, 
other methods like at random parcelling should be based on the assumption that all items are 
interchangeable, large sample size, many items, high item communality, low item diversity (40). 
The parcels developed for the CFA of the SCREENIVF were theory based, taking into account 
the conceptual relatedness (that the parcel reflected the different components of the construct 
e.g., depression there was vegetative symptoms, cognitive symptoms) of the items grouped 
within a parcel. See Figure 1. 
Measurement invariance (MI) was tested to investigate whether the construct of the 
SCREENIVF has the same structure across gender. With MI it can be demonstrated that men and 
women understand the questions of the SCREENIVF and the fundamental latent factor in the 
same way (42), and that the pattern of interrelationships among the latent factors are similar. The 
threshold values to assess MI are:  CFI>0.95 and RMSEA <0.05 (42). If the model with 
constrained parameters (loading, intercept, mean) differs significantly from the unconstrained 
model this is indicative of variance according to gender.  
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To test the criterion validity (concurrent and predictive) of the SCREENIVF the sensitivity, 
specificity, positive predictive value and negative predictive value were measured and a 
prediction model was developed. According to COSMIN the criterion validity can be assessed by 
the use of a gold standard (43) but this assumes measurement without error, which is unrealistic 
for measures of anxiety and depression. A good alternative is to use instead a ‘reference 
standard’ and well validated criterion measure of the diagnosis or condition in question (19). In 
this study the HADS was used as a criterion measure for emotional maladjustment. The cut off 
score of the HADS for the anxiety and depression scales were ≥ 8. Sensitivity refers to the ability 
of the SCREENIVF to correctly identify those patients with emotional maladjustment while 
specificity refers to the ability of the test to correctly identify those patients without emotional 
maladjustment (44). Positive predictive value (PPV) refers to the likelihood that a patient has 
emotional maladjustment given that the test result is positive. In this study, this means that 
patients identified as ‘at risk’ at the start of treatment (T1), will have high scores for anxiety and 
depression during the waiting period (time 2) or six weeks after treatment failure (T3). Negative 
predictive value (NPV) refers to the likelihood that a patient does not have emotional 
maladjustment given that the test result is negative (44). In this study, this means patients 
identified as ‘not at risk’ at the start of treatment (time 1), will not have high scores for anxiety 
and depression during the waiting period (time 2) or six weeks after treatment failure (time 3). 
To further explore the concurrent and predictive validity of the SCREENIVF, and assist its use in 
clinics, prediction models were developed to evaluate its efficacy to predict patients’ levels of 
emotional maladjustment during or after the course of IVF treatment. Concurrent validity is the 
degree to which the scores of the SCREENIVF are an adequate reflection of the scores on the 
HADS measured at the same time (T1). Predictive value is the degree to which the scores of the 
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SCREENIVF predict the scores on the HADS in the future (time 2, time 3). The prediction 
models were developed using linear (ordinary least square) regression for men and women 
separately. All variables were entered at the same time. The predictor variables were the sum 
scores on each of the 5 subscales of the SCREENIVF according to the development of the 
questionnaire (16). The outcome used for the prediction model was the HADS score at baseline, 
day 10 of the waiting period and 6 weeks after embryo transfer. To account for missing data for 
the prediction model, multiple imputation was performed using R with the multivariate 
imputation by chained equations (MICE) package using default settings; 20 imputation data sets 
were generated (45). Multiple imputation is preferable over other analysis in several 
circumstances (46). In this study data was missing at random, and variables chosen for 
imputation have a correlation with the incomplete variables, furthermore the percentage missing 
values varied between 3-41%. The variables used for imputation were: having previous children 
(yes/no), age (years), knowing why one was infertile (yes/no), any previous miscarriage (yes/no) 
and previous use of counselling for infertility (yes/no). For the imputation, only the data were 
used for males and females where data was available on at least one subscale of SCREENIVF. 
Imputation for males and females was done separately. When one subscale was not completed 
the case was deleted. See for an overview of the analysis supplemental table 1. 
 
Results  
Sample characteristics 
The baseline characteristics are described in Table 1. More women (n=487) than men (n=426) 
agreed to participate in the study, and all participants were heterosexual couples. Mean age was 
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higher for men (t=10.67, df=415, p=0.000). More women (52.1%) than men (31.9%) were at risk 
for emotional maladjustment before the start of an IVF/ICSI treatment on one or more of the 
subscales of the SCREENIVF (x2=57.5, df=1, p=0.009)  
The number of women who returned the SCREENIVF at Time 1 was n=468 (96.1%) and men 
n=383 (90%). The number of women who returned the HADS at time 1 was n=471 (97%) and 
men n=387 (91%), at time 2 women n=398 (82%) and men n=326 (77%), at time 3 women 
n=354 (73%) and men n=285 (67%). The number of women in the control group who returned 
the HADS at time 2 was n=102 (82%) and at time 3 was n=90 (73%). 
 
Construct validity 
The confirmatory factor analysis was done separately for women and men (see Table 2 and 
Figure 1). The model fit statistics showed good fit based on CFI and RMSEA for men and 
women (for women: CFI=0.992; RMSEA=0.038 [90% CI: 0.022-0.054]; for men: CFI=0.994; 
RMSEA =0.026 [90% CI: 0.000-0.046]). As shown in Figure 1, all standardized factor loadings 
of the parcels were high between 0.700-0.953 and significant (p=0.000) and all five latent factors 
of the SCREENIVF were significantly interrelated (p=0.000). The correlations between the 
factors anxiety and depression were the highest (women=0.842, men=0.726) and between social 
support and helplessness the lowest (women=0.215, men=0.150). Consistent with this analysis, 
the fit indices for measurement invariance across gender showed a RMSEA > 0.05 for intercepts 
and means which indicated that measurement is not invariant (see supplemental table 2).   
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Criterion validity 
The criterion validity was analysed separately for women and men based on the differential 
results of the CFA. Two methods are used to test the criterion validity of the SCREENIVF, the 
sensitivity, specificity, positive predictive, negative predictive value were measured and a 
prediction model was developed. 
Sensitivity, specificity, positive and negative predictive value  
On T1 the results for concurrent validity are displayed and the predictive validity at time 2 and 
time 3. The results for sensitivity, specificity, positive and negative predictive value are 
presented in Table 3. Across time, sensitivity scores for HADS subscale in women ranged from 
61%-98%, specificity 53%-65%, PPV 13%-56%, NPV 70%-99%. The sensitivity scores for men 
ranged from 38%-100%, specificity 71%-75%, PPV 9%-27%, NPV 92%-100%. Overall, the 
scores for sensitivity and NPV are the highest at time 1. This means that the SCREENIVF 
completed by women and men is better in identifying patients at risk for emotional 
maladjustment (sensitivity) and better in correctly screening patients who have not emotional 
maladjustment (NPV) at the start of the treatment (time 1) than during (time 2) or after treatment 
(time 3).  
The NPV is better at time 1, time 2, and time 3 than de PPV for both women and men. This 
means the SCREENIVF is better in correctly screening patients who do have not emotional 
maladjustment than screening patients who have emotional maladjustment. The use of the 
SCREENIVF leads to more false positive then false negative results. (See supplemental Figures 
1 and 2).  
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Prediction model 
The results of the prediction model are presented in Supplemental table 3. At time 1 the results 
for concurrent validity are displayed, at time 2 and time 3 of predictive validity. A linear 
regression model investigated whether the subscales of the SCREENIVF at time 1 predicted 
anxiety and depression levels as measured with the HADS at time 1, time 2 and time 3. The 
results for women show that sum score subscales of the SCREENIVF explained 68.7 % 
(R2=0.687) of the variance in the HADS on time 1, 42.5% (R2=0.425) at time 2 and 38.9% 
(R2=0.389) at time 3. As shown in Table 5, the predictors anxiety and depression subscales have 
a significant contribution to the model at time 1 (p<0.05), the predictor anxiety and helplessness 
subscales have a significant contribution to the model at time 2  (p<0.05) and the predictor 
anxiety has a significant contribution to the model at time 3 (p<0.05). The results for men show 
that 58.1% (R2=0.581) of the variance in the HADS on time 1, 46.5% (R2=0.465) at time 2 and 
37.3% (R2 =0.373) at time 3 is explained by the predictors, sum score subscales of the 
SCREENIVF. The predictors anxiety and depression subscales have a significant contribution to 
the model at time 1, 2 and 3 (p<0.05). The predictor social support subscale has a significant 
contribution to the model at time 1 and helplessness at time 2 (p<0.05). 
 
Discussion 
In this study the construct and criterion validity (concurrent and predictive) of the SCREENIVF 
were investigated among women and men undergoing fertility treatment. Results show that the 
concurrent validity of the SCREENIVF is better than the predictive validity. Analyses revealed 
that the circumstances in which SCREENIVF would be most effectively used in fertility clinics 
15 
 
are at the start of treatment, in women and men to rule out emotional maladjustment or to predict 
people NOT at risk for depression during the waiting period or after treatment. The SCREENIVF 
is not good in predicting emotional maladjustment during or after treatment. The advantage of 
using the SCREENIVF, with respect to other instruments like the HADS, is that it covers 
cognitions, emotions and support using items worded in a way that will resonate with the lived 
experience of people undergoing treatment. The future evaluation studies proposed comprise 
prospective longitudinal qualitative and quantitative studies to better understand why men and 
women respond differently to items, why negative predictive values are better than positive 
predictive values.  
The construct validity of the SCREENIVF is good. The CFA shows that the hypothesised five 
factor structure of the SCREENIVF with subscales of depression, anxiety, helplessness, 
acceptance and social support has a good fit to the observed data.   
Men and women do not interpret or respond to the SCREENIVF items in the same way. Our 
study confirms that the measurement model for women and men is different and that criterion 
and predictive validity are different for women and men. The Portuguese validation study of the 
SCREENIVF revealed a significant structural and measurement invariance for gender (15). In a 
cross sectional study where 946 women and 670 partners completed the SCREENIVF women 
were significantly more at risk than their partner on all subscale of the SCREENIVF except on 
social support (2). SCREENIVF was originally developed based on research among women in an 
IVF treatment (13).  Our results suggest that more in-depth qualitative research is necessary to 
identify why gender affects responses to items, and whether the differences suggest a need for 
scoring and cut off values of the SCREENIVF to be gender based.  
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The concurrent validity of the SCREENIVF is better than the predictive validity. Sensitivity, 
NPV and the results of the prediction model show that results of time 1 are better than at time 2 
and time 3. Results are somewhat different from another Dutch validation study of the 
SCREENIVF with a sensitivity of 69%, specificity of 77%, PPV 48% and NPV 89% (16). In 
both studies the PPV was very low. Differences could be due to the fact that in our study the 
HADS was used as a criterion measure and separate analyses were done for anxiety and 
depression while in the other Dutch validation study the subscales anxiety and depression of the 
SCREENIVF were used with a dichotomous variable of yes or no high scores on anxiety and/or 
depression (16). We would argue that using subscales of the SCREENIVF at both times 
confounds reliability and prediction, and makes prediction seem better than it actually is. The 
results show that fertility clinic staff can generally feel confident that on average when men and 
women do not score as at risk on SCREENIVF they will not have depression now or later in the 
treatment cycle (i.e., during waiting or after results) because all negative predictive values were 
more than 96% for depression. At a practical level predicting absence of maladjustment is useful 
because it means that these patients will not require support for depression at a clinic, conserving 
resources for others.  
Whilst one can feel confident about the absence of disorder (on average), the same cannot be 
said about the presence of disorder. Positive predictive values of the SCREENIVF were poor. In 
the present study people judged to be at risk at T1 were unlikely to have emotional 
maladjustment at time 2 or time 3. Several reasons could exist for this outcome. Positive and 
negative predictive values are influenced by the prevalence of the disease in the population tested 
(44, 47). Several studies suggest a low prevalence of anxiety and depression among women and 
men attending an IVF clinic (48, 49). Positive and negative predictive values are also influenced 
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by the sensitivity and the specificity and these are influenced by the cut off scores of the 
SCREENIVF. In our study the cut off scores were based on the first Dutch validation study of 
the SCREENIVF, one standard deviation above or below the mean scores (16). It could be that 
cut-off scores were not correctly set. In the Portuguese validation study more patients scored 
above the cut-off scores (15). Perhaps there are transcultural differences for cut off scores. More 
research has to be conducted about the correct cut-off scores for instance with Area Under the 
Curve and Receiver Operating Characteristic. It should also be investigated, whether adding 
prognostic variables available at the start of IVF (e.g., age, previous pregnancy, with/without 
IVF) to the SCREENIVF, improves positive prediction rates.  
The prediction model showed that not all subscales of the SCREENIVF had a significant 
contribution to the model. The question arises whether all five risk factors are necessary to detect 
emotional maladjustment. A reason why not all subscales contribute to the model could be due to 
the fact that prediction models are difficult to develop because of the reactive and dynamic 
nature of emotional maladjustment. Distress levels fluctuate according to events during 
treatments such as oocyte retrieval and embryo transfer (50). External factors like stressful life 
events can also affect distress during treatment (51). These influences make it difficult to predict 
with high accuracy emotional maladjustment.  
In the analysis the SCREENIVF was investigated as a stand-alone tool without considering other 
variables that could influence emotions during and after treatment. A stand-alone tool means it 
does not take into account any other psychosocial or biomedical variables that could influence 
(post) treatment emotions. For example, events that occur during the cycle (e.g., number of 
oocytes) or after it (e.g., pregnancy outcome) because these data are not available at the start of 
treatment when SCREENIVF is administered. Analytically this was necessary to investigate the 
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claim that the SCREENIVF could predict future emotional maladjustment from the start of 
treatment. To include these future events at the start of treatment, future research should consider 
including prognostic information, for example patient’s predicted chance of success at baseline 
using predictive models (52). The inclusion of such variables may improve the predictive ability 
of SCREENIVF. Alternatively, it could be argued that the SCREENIVF should (and did not) 
predict emotional maladjustment regardless of outcome, for example predict the level of anxiety 
in response to pregnancy (e.g., fear about miscarriage). A recent review confirmed the 
importance of the five risk factors of the SCREENIVF associated with emotional adjustment 
(53).  
Although the predictive validity is not as good as the concurrent validity there may still be value 
in using SCREENIVF. First, SCREENIVF has face validity in that constructs and items were 
selected and tested with patients undergoing fertility treatment, which probably gives it more 
face validity than solely generic versions but also items can resonate with patients validating 
their own experiences of, for example, helplessness. Second, using all the SCREENIVF 
subscales at the start of a fertility treatment gives healthcare professionals a good profile of areas 
of vulnerability (cognition, emotion, support). This is a good starting point to talk about the 
specific support women and men need from healthcare professionals working in a fertility clinic, 
helping individualized care to be delivered. Practical aspects such as the easy availability, clear 
scoring guidelines and possibility to rule out people needing help also makes it worthwhile. 
This study had some limitations that should be mentioned. A limitation was the HADS, with two 
subscales, that was used as a criterion measure for the SCREENIVF with five subscales. The 
HADS was used because it is a well validated questionnaire and no comparable instrument like 
the SCREENIVF exists. The present study was nested in a RCT and only women of the control 
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group who were not assigned to the intervention could be included for the second and third time 
measurement while all the data of the men could be used because they did not participate in the 
RCT. This could represent some bias in that women who received the intervention could have 
had an influence on their respective male partner’s scores across time. Although the intervention 
was given to women and not men, it could be that women shared the PRCI with their partner. 
Analyses showed there were no significant differences between the anxiety and depression 
scores of men according to their partner’s group assignment but such bias cannot be ruled out. 
Another weakness could be that only patients willing to participate in a RCT about a 
psychological intervention were sampled, and this could also have introduced bias that 
minimized the SCREENIVF to predict maladjustment.  Another limitation was the missing data. 
In this study the method of multiple imputation was used, a method that is likely to be superior 
over other methods to deal with missing data (46).  
The strength of this study is the use of COSMIN. The COSMIN checklist provides a systematic 
way of not only assessing the quality of other studies on measurement properties but it can also 
be helpful in designing or reporting an own study on measurement properties (18). Another 
strength is the prospective and longitudinal design with men and women focusing on points in 
the treatment trajectory where patients with psychological vulnerability could experience 
emotional maladjustment, namely, at the start of treatment, during the waiting period and after 
treatment results are known. 
The conclusion of this study is that the SCREENIVF can be used to identify women and men 
with emotional maladjustment before the start of a fertility treatment. The results of the 
SCREENIVF give healthcare workers an objective instrument to talk about emotional 
maladjustment in different areas with their patients. Based on these results SCREENIVF should 
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not be used as a predictive tool until more research is done to improve the predictive value of 
SCREENIVF.   
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